Pancreatic cancer symptoms may be relieved by THC

A recent study suggests that patients with pancreatic cancer who used daily doses of at least 10 mg of THC showed average improvement across more symptoms than those who consumed lower doses. The finding, however, is preliminary and does not mean that a specific dose of THC is indicated for all patients.

What did the study discover about pancreatic cancer?

Published in September 2026 in the scientific journal The Oncologist, the study analyzed data from the CANPAN trial, which followed 32 individuals with locally advanced or metastatic pancreatic adenocarcinoma who had no prior experience with cannabis.

Among the participants, 23 used cannabis during the intervention period. However, only 16 had complete data before and after initiating use, an important factor for interpreting the results with caution.

The analysis observed a relationship between the daily amount of THC used and the improvement of certain symptoms.

More specifically, higher average doses were associated with greater improvement in anxiety and insomnia.

Medical cannabis and THC: what changed with the dose?

One of the most notable findings was the comparison between participants who used less than 10 mg of THC per day and those who used 10 mg or more.

According to researchers, the group receiving 10 mg or more of THC daily showed an average improvement across four symptoms, while those who used lower doses had an average improvement across 2.1 symptoms.

Four weeks after starting cannabis, the median daily dose was 10 mg in the group that began the intervention earlier and 9.3 mg in the group that started later.

LEARN MORE: THC and cancer: four days can alter tumor cells

Can medical cannabis help with cancer symptoms?

The research did not evaluate cannabis as a treatment capable of eliminating or controlling pancreatic cancer.

The focus was on symptom management and the relationship between the THC dose and patients' perception of their health status.

This detail makes all the difference.

Pancreatic cancer can cause a complex combination of physical and emotional symptoms. Therefore, supportive care strategies that help improve well-being can be relevant within an individualized approach.

In the study, the most consistent association appeared precisely in psychological symptoms: anxiety and insomnia. The correlation between the average daily dose of THC and symptom improvement was 0.52 for anxiety and 0.53 for insomnia.

What questions remain unanswered?

Despite the promising results, the researchers themselves highlight important limitations.

The first is sample size. The CANPAN trial began with only 32 participants, and only half provided complete symptom data at the end of 16 weeks.

Additionally, the THC dose was not randomly assigned to directly assess which amount would be most effective. Therefore, the findings demonstrate an association, rather than a cause-and-effect relationship.

In other words: the study does not allow claiming that increasing THC will necessarily provide a patient with greater relief.

It is also not possible to translate the 10 mg observed in the study into a universal dosing recommendation.

LEARN MORE: Study analyzes how cannabis compounds interact with common cancers
 

What lies ahead?

For the authors, the findings may help design larger clinical trials on the use of cannabis as supportive care for people with pancreatic cancer.

The observed link between THC dose, anxiety, insomnia, and multi-symptom improvement offers a clue that still needs to be investigated in studies with more participants and longer follow-up periods.

For now, the takeaway is one of caution: while the results are interesting, they do not yet establish a standard dose of THC for oncology patients.

Any use of medical cannabis during cancer treatment should be discussed with the healthcare team, taking into account current medications, clinical conditions, and care goals.